John Pancari's questions to FRACTYL HEALTH (GUTS) leadership • Q2 2025
Question
John Pancari, on behalf of Michael Dufry at Evercore ISI, questioned the contribution of GLP-1 therapy to outcomes in the German two-year follow-up and asked about the protocols for weight measurement to ensure accuracy.
Answer
Harith Rajagopalan, Co-Founder, CEO & Director, clarified that GLP-1 use by a few patients in the German study did not affect the interpretation of Revita's efficacy, as the weight loss signal was consistent among all patients. He also confirmed that the company employs rigorous, standardized protocols for scale calibration and weight measurement to control for variability.